NBIX - Neurocrine Biosciences - Stock & Dividends

Neurocrine Biosciences Inc. is a pharmaceutical company that focuses on discovering, developing, and marketing innovative treatments for complex neurological, neuroendocrine, and neuropsychiatric disorders. Their products aim to improve the lives of patients suffering from rare and debilitating conditions.

The company's portfolio includes INGREZZA, a treatment for tardive dyskinesia and chorea associated with Huntington's disease, as well as ALKINDI for adrenal insufficiency. They also offer Efmody capsules for classic congenital adrenal hyperplasia, Orilissa tablets for endometriosis, and Oriahnn capsules for uterine fibroids. These products have made a significant impact on the lives of patients and their families.

Neurocrine Biosciences has a robust pipeline of product candidates in clinical development, including valbenazine to treat dyskinetic cerebral palsy, NBI-921352 for developmental and epileptic encephalopathy syndrome, and NBI-827104 for epileptic encephalopathy with continuous spike-and-wave during sleep. They are also working on treatments for movement disorders, congenital adrenal hyperplasia, and cognitive impairment related to schizophrenia, among others.

The company has established strategic partnerships with leading pharmaceutical companies, including Heptares Therapeutics, Takeda Pharmaceutical, Idorsia Pharmaceuticals, and AbbVie Inc., to name a few. These collaborations enable Neurocrine Biosciences to leverage their expertise and resources to accelerate the development of innovative treatments.

Founded in 1992, Neurocrine Biosciences is headquartered in San Diego, California, and has a strong commitment to improving patient outcomes and advancing the field of neuroscience. With a focus on innovation, collaboration, and patient-centricity, the company is well-positioned to continue making a meaningful impact in the lives of patients and their families.